Effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer
A protocol for systematic review and meta-analysis

Jiang-Yi Feng, MM, Ge Li, MM, Yi Guo, MD, Yun-Han Gao, MB, Sha-Ying Ma, MB

Abstract

Background: Radiotherapy is one of the essential components of breast cancer treatment. It destroys the remaining cells in the chest area after breast cancer surgery and is useful for reducing the necessity of mastectomies. As a single dose of radiation at the time of breast conserving surgery, intraoperative radiotherapy delivers radiotherapy directly and accurately to the tumor itself or the tumor bed whilst delivering minimal dose to the surrounding normal tissues. Hypofractionated postmastectomy radiotherapy with shorter and more convenient hypofractionated dose schedules might help to treat more patients and reduce cost. We will conduct a comprehensive systematic review and meta-analysis to compare the effectiveness of these 2 therapies in the management of early stage breast cancer.

Methods: Four English databases (PubMed, Embase, Cochrane Library, and Web of Science) and 3 Chinese databases (China National Knowledge Infrastructure, China Science and Technology Journal Database, and Chinese Biomedical Literature Database) will be searched from inception of databases to December 2020 without language limitation. Two reviewers will independently conduct selection of studies, data extraction and management, and assessment of risk of bias. Any disagreement will be resolved by the third reviewer. Review Manager 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK) will be used for data synthesis. Cochrane risk of bias assessment tool will be used to assess the risk of bias.

Results: This study will provide a systematic synthesis of current published data to compare the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer.

Conclusions: This systematic review and meta-analysis will provide clinical evidence for the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer, and inform our understanding of the value of intraoperative radiotherapy and hypofractionated postmastectomy radiotherapy for early stage breast cancer.

Study registration number: INPLASY2020110115.

Abbreviations: PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCTs = randomized controlled trials.

Keywords: breast cancer, hypofractionated postmastectomy radiotherapy, intraoperative radiotherapy, meta-analysis, protocol, systematic review

1. Introduction

Breast cancer has been the most common cancer and the primary cause of mortality due to cancer in women. In developed countries, the 5-year survival rate is about 80%, and in developing countries, it is about 40%. Enhancement in screening mammography and management is beneficial for detecting early stage breast cancer and reducing mortality due to breast cancer. Surgery such as lumpectomy, mastectomy and reconstructive surgery is the foremost management strategy for breast cancer patients. Radiotherapy is one of the essential components of breast cancer treatment. It is useful for reducing the necessity of mastectomies and destroys the remaining cells in the chest area after breast cancer surgery. Many randomized controlled trials (RCTs) and meta-analyses reported that radiotherapy as an adjuvant treatment showed benefits in both locoregional control and overall survival.

Intraoperative radiotherapy is a single dose of radiation at the time of breast conserving surgery. It has been used in a range of
tumor sites, including the breast, head and neck, lung, and so on.\textsuperscript{[11–13]} Intraoperative radiotherapy delivers radiotherapy directly and accurately to the tumor itself or the tumor bed whilst delivering minimal dose to the surrounding normal tissues.\textsuperscript{[14]} One study showed that the recurrence rate of ipsilateral breast tumor in intraoperative radiotherapy group was significantly greater than in external radiotherapy group, and overall survival did not differ between groups.\textsuperscript{[15]}

Hypofractionated postmastectomy radiotherapy with shorter and more convenient hypofractionated dose schedules might help to treat more patients and reduce cost.\textsuperscript{[16]} One study showed hypofractionated postmastectomy radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radiotherapy in high-risk breast cancer patients, and it provided better convenience.\textsuperscript{[17]} One study found that Hypofractionated postmastectomy radiotherapy is cost-effective compared with conventional radiotherapy and intraoperative radiotherapy for early stage breast cancer patients.\textsuperscript{[18]} Guenzi M et al evaluated the local recurrence in patients with early breast cancer who underwent intraoperative radiationtherapy or hypofractionated postmastectomy radiotherapy, and the result showed that at 6 years a significant higher rate of local recurrence occurred in intraoperative radiationtherapy group.\textsuperscript{[19]}

Up to now, no systematic review or meta-analysis has been performed to compare the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer. Therefore, we will conduct a comprehensive systematic review and meta-analysis to compare the effectiveness of these 2 therapies in the management of early stage breast cancer.

2. Methods

2.1. Study registration

This study has been registered on INPLASY (INPLASY2020110115). This meta-analysis will be performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement checklist.\textsuperscript{[20]}

2.2. Eligibility criteria for study selection

2.2.1. Types of studies. RCTs comparing the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer will be included without language limitation.

2.2.2. Types of participants. Participants diagnosed with early stage breast cancer will be included.

2.2.3. Types of interventions. In the treatment group, patients were given intraoperative radiotherapy. In the control group, patients were given hypofractionated postmastectomy radiotherapy.

2.2.4. Types of outcomes. The recurrence rate and the rate of 5-year disease-free survival will be designated as the primary outcome. Adverse events will be designated as the secondary outcome.

2.3. Search strategy

Four English databases (PubMed, Embase, Cochrane Library, and Web of Science) and 3 Chinese databases (China National Knowledge Infrastructure, China Science and Technology Journal Database, and Chinese Biomedical Literature Database) will be searched from inception of databases to December 2020 without language limitation. Additional trials will be searched by reviewing the reference lists of the retrieved articles, conference proceedings, and gray literature. The detailed search strategy for PubMed is shown in Table 1. The similar search strategies will be used for other electronic databases.

2.4. Selection of studies

The searched articles will be integrated into Endnote X7 (Thomas Reuters, CA) and duplicates will be excluded by software. Two reviewers will independently scan titles and abstracts according to the eligibility criteria. The remaining records will be read by full texts. Then final included studies will be determined. Any disagreement will be resolved by the third reviewer. A PRISMA flowchart will be designed to describe the details of selection process.

2.5. Data extraction and management

Two reviewers will independently conduct data extraction. Any disagreement will be resolved by the third reviewer. The following information from each study will be extracted: authors name, publication year, journal, study design, participants baseline characteristics, number of participants in each arm, experimental intervention, control intervention, and outcomes. If the trials have more than 2 arms, only the interest-reported information and data will be extracted. We will try our best to contact original authors for detailed information by email or phone if required information is missing.

2.6. Assessment of risk of bias

Cochrane risk of bias assessment tool will be used to assess the risk of bias of the included studies. Seven items such as random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete

| Table 1 | Search strategy of PubMed. |
|---------|---------------------------|
| Number  | Search terms               |
| 1       | breast cancer              |
| 2       | breast carcinoma           |
| 3       | mammary cancer             |
| 4       | breast tumor               |
| 5       | Or 1–4                     |
| 6       | intraoperative radiotherapy |
| 7       | IORT                       |
| 8       | intra-operative radiation  |
| 9       | therapy                    |
| 10      | intraoperative irradiation  |
| 11      | Or 6–9                     |
| 12      | hypofractionated            |
| 13      | hypofractionated radiation  |
| 14      | hypofractionated radiotherapy |
| 15      | postmastectomy radiotherapy|
| 16      | Randomized controlled trial|
| 17      | Clinical trial             |
| 18      | Random                     |
| 19      | Trial                      |
| 20      | Or 16–19                   |
| 21      | 5 and 10 and 15 and 20     |
outcome data, selective reporting and other bias will be evaluated by 2 reviews independently. Any disagreement will be resolved by the third reviewer.

2.7. Data synthesis and analysis

2.7.1. Data synthesis. Review Manager 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK) will be used for data synthesis. Risk ratio will be used for dichotomous outcomes with 95% confidence interval. Continuous outcomes will be presented as mean difference or standardized mean difference with 95% confidence interval. We will use I² test to identify heterogeneity. The I² value >50% means significant heterogeneity, and the random effects model will be used. The I² value ≤50% means minor heterogeneity, and the fixed effects model will be utilized.

2.7.2. Subgroup analysis. Subgroup analysis will be performed based on the different participant characteristics and outcome indicators to check the potential heterogeneity and inconsistency. If significant heterogeneity still exists after subgroup analysis, meta-analysis will not be pooled, and descriptive summary will be reported.

2.7.3. Sensitivity analysis. Sensitivity analysis will be performed to test the robustness and reliability of pooled results by eliminating studies in low quality.

2.7.4. Reporting bias. Publication bias will be assessed with funnel plot and Egger regression analysis if sufficient trials (≥10 trials) are included.

2.7.5. Ethics and dissemination. Ethical approval is not necessary because this study is based on literature analysis. The results of this study will be published in a peer-reviewed journal.

3. Discussion

To our knowledge, this is the first systematic review and meta-analysis to conduct a comprehensive literature search and provide a systematic synthesis of current published data to compare the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer. Four English databases and 3 Chinese databases will be searched to avoid missing any potential eligible studies, and apply rigorous methodology to examine studies reporting intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer. This systematic review and meta-analysis will provide clinical evidence for the effectiveness of intraoperative radiotherapy vs hypofractionated postmastectomy radiotherapy for early stage breast cancer, and inform our understanding of the value of intraoperative radiotherapy and hypofractionated postmastectomy radiotherapy. We believe that the conclusions drawn from this study may be beneficial to patients, clinicians, and policy makers.

Author contributions

Conceptualization: Jiang-yi Feng, Ge Li, Sha-ying Ma.
Data curation: Jiang-yi Feng, Ge Li, Yi Guo.
Formal analysis: Ge Li, Yi Guo, Yun-han Gao.
Investigation: Ge Li, Yi Guo, Yun-han Gao.

Methodology: Jiang-yi Feng, Ge Li, Sha-ying Ma.
Project administration: Sha-ying Ma.
Resources: Jiang-yi Feng, Ge Li.
Software: Yi Guo, Yun-han Gao.
Supervision: Yi Guo, Yun-han Gao.
Validation: Sha-ying Ma.
Visualization: Jiang-yi Feng.
Writing – original draft: Jiang-yi Feng, Ge Li.
Writing – review & editing: Jiang-yi Feng, Ge Li, Yi Guo, Yun-han Gao, Sha-ying Ma.

References

[1] Anastasiadi Z, Lianos GD, Ignatiadou E, et al. Breast cancer in young women: an overview. Updates Surg 2017;69:313–7.
[2] Wörmann B. Breast cancer: basics, screening, diagnostics and treatment. Med Monatschr Pharrn 2017;40:55–64.
[3] Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 2019;1152:51–64.
[4] Winters S, Martin C, Murphy D, et al. Breast cancer epidemiology, prevention, and screening, Prog Mol Biol Tran Sci 2017;151:1–32.
[5] Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat 2016;19:395–406.
[6] Smnadaturi S, Kwong A, Hartman M, et al. Breast-conserving surgery versus mastectomy in young women with breast cancer in Asian settings. BJS Open 2018;3:48–55.
[7] Kaufman CS. Increasing role of oncoplastic surgery for breast cancer. Curr Oncol Rep 2019;21:111.
[8] Bradley JA, Mendenhall NP. Novel radiotherapy techniques for breast cancer. Annu Rev Med 2016;69:277–88.
[9] Pfeffer RM. Radiotherapy for breast cancer: curing the cancer while protecting the heart. Isr Med Assoc J 2018;20:582–3.
[10] Taylor CW, Kirby AM. Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol) 2015;27:621–9.
[11] Lipsitt A, Barrett S, Haruna F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: a systematic review and meta-analysis. Breast 2017;32:144–55.
[12] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017;390:1048–60.
[13] Krug D, Baumann R, Budach W, et al. Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer: a systematic review. Strahlenther Onkol 2018;194:607–18.
[14] Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019;394:2155–64.
[15] Sjostrom M, Lundstedt D, Hartman L, et al. Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the Swedish breast cancer group 91 radiotherapy randomized clinical trial. J Clin Oncol 2017;35:3222–9.
[16] Sedlmayer F, Reisamer R, Wenz F, et al. Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol 2017;12:23.
[17] Giordano FA, Wenz F, Petrucco K. Rational for intraoperative radiotherapy in glioblastoma. J Neurosurg Sci 2016;60:350–6.
[18] Krengli M, Pisani C, Deantonio L, et al. Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers. Radiat Oncol 2017;12:18.
[19] Esposito E, Compagna R, Rinaldo M, et al. Intraoperative radiotherapy in elderly patients with breast cancer: is there a clinical applicability? Review of the current evidence. Int J Surg 2016;33:88–91.
[20] Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013;14:1269–77.
[21] Castaneda SA, Strasser J. Updates in the treatment of breast cancer with radiotherapy. Surg Oncol Clin N Am 2017;26:371–82.
[22] Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019;20:352–60.

[23] Deshmukh AA, Shirvani SM, Lal L, et al. Cost-effectiveness analysis comparing conventional, hypofractionated, and intraoperative radiotherapy for early-stage breast cancer. J Natl Cancer Inst 2017;109:djx068.

[24] Guenzi M, Bonzano E, Corvò R, et al. Comparison of local recurrence among early breast cancer patients treated with electron intraoperative radiotherapy vs hypofractionated photon radiotherapy an observational study. Front Oncol 2018;8:207.

[25] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.